[177Lu]Lu-ABY-271

[177Lu]Lu-ABY-271 is a **radiopharmaceutical** designed for targeted radionuclide therapy of cancer. It is composed of an Affibody molecule (ABY-271) that binds specifically to the human epidermal growth factor receptor type 2 (**HER2**), making it suitable for the treatment of HER2-positive tumors such as metastatic breast cancer. The molecule includes an engineered albumin-binding domain (ABD) fused to the Affibody, which increases bioavailability and reduces renal uptake compared to non-ABD-fused versions. The construct is site-specifically labeled with the beta-emitting radionuclide **lutetium-177 (177Lu)** using a DOTA chelator; in ABY-271, the chelator is conjugated at the back of the ABD to further optimize albumin binding, tumor uptake, and biodistribution. The primary mechanism of action relies on selective binding to HER2-expressing cells and local delivery of cytotoxic radiation from lutetium-177, thereby inducing tumor cell death[1][5][6][8].

Other names

Lutetium-177 ABY 271Lutetium177 ABY 271Lutetium 177 ABY 271